Search
cabotegravir (Apretude)
Indications:
- treatment of HIV1 infection
- for use in combination with rilpivirine (IM) orabacavir-lamivudine (PO)
- pre-exposure HIV1 prophylaxis
Dosage:
- long-acting cabotegravir plus rilpivirine every 4 weeks (2 injections) or 8 weeks (3 injections) IM [1,2]
Injection: 200 mg/mL
Monitor:
- HIV-1 RNA
Mechanism of action:
- integrase strand transfer inhibitor
Interactions
drug adverse effects of antiretroviral agents
General
antiretroviral agent
Database Correlations
PUBCHEM correlations
References
- Margolis DA, Gonzalez-Garcia J, Stellbrink HJ et al
Long-acting intramuscular cabotegravir and rilpivirine in adults
with HIV-1 infection (LATTE-2): 96-week results of a randomised,
open-label, phase 2b, non-inferiority trial.
Lancet. July 24, 2017
PMID: 28750935
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31917-7/fulltext
- Boyd MA, Cooper DA
Long-acting injectable ART: next revolution in HIV?
Lancet. July 24, 2017
PMID: 28750936
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31962-1/fulltext
- FDA News Release. Jan 21, 2021
FDA Approves First Extended-Release, Injectable Drug Regimen for Adults
Living with HIV.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv
- Saag MS, Gandhi RT, Hoy JF, et al
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults.
2020 Recommendations of the International Antiviral Society-USA Panel.
JAMA. Published online October 14, 2020
PMID: 33052386
https://jamanetwork.com/journals/jama/fullarticle/2771873
- Gandhi RT, Bedimo R, Hoy JF et al
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults.
2022 Recommendations of the International Antiviral Society - USA Panel.
JAMA. Published online December 1, 2022.
PMID: 36454551
https://jamanetwork.com/journals/jama/fullarticle/2799240
Component-of
cabotegravir/rilpivirine (Cabenuva)